Analysis of Eribulin Mesylate Dosing Modifications Impact on Administration Persistence in Patients With Metastatic Breast Cancer (Mbc)

Value in Health - United Kingdom
doi 10.1016/j.jval.2015.09.1043
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Eribulin Mesylate in the Treatment of Metastatic Breast Cancer

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2012English

Eribulin Suppresses New Metastases in Patients With Metastatic Breast Cancer

In Vivo
BiochemistryMedicineGeneticsPharmacologyMolecular Biology
2020English

Oral Paclitaxel in the Treatment of Metastatic Breast Cancer (MBC) Patients.

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2019English

The Impacts of Inclusion in Clinical Trials on Outcomes Among Patients With Metastatic Breast Cancer (MBC)

PLoS ONE
Multidisciplinary
2016English

Eribulin in Pretreated Metastatic Breast Cancer Patients: Results of the TROTTER Trial—a Multicenter Retrospective Study of Eribulin in Real Life

SpringerPlus
Multidisciplinary
2016English

Use of Eribulin as an Earlier-Line Chemotherapy for Patients With HER2-negative Metastatic Breast Cancer

Journal of Cancer
Oncology
2020English

Outcome of Eribulin as a Late Treatment Line for Thai Metastatic Breast Cancer Patients

OncoTargets and Therapy
OncologyPharmacology
2018English

Impact of Systemic Therapy on Circulating Leukocyte Populations in Patients With Metastatic Breast Cancer

Scientific Reports
Multidisciplinary
2019English

Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate With Trastuzumab as First-Line Therapy for Locally Recurrent or Metastatic HER2-Positive Breast Cancer

Clinical Breast Cancer
Cancer ResearchOncology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy